Sufentanil (Zalviso®)

Assessment Status Assessment process complete
Drug Sufentanil
Brand Zalviso®
Indication For the management of acute moderate to severe post-operative pain in adult patients.
Assessment Process
Rapid review commissioned 14/03/2016
Rapid review completed 22/03/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended.
Full pharmacoeconomic assessment commissioned by HSE 16/08/2017
Pre-submission consultation with Applicant 24/05/2017
Full submission received from Applicant 31/10/2017
Additional follow-up to Preliminary Review sent to Applicant 15/06/2018
NCPE assessment outcome The assessment of sufentanil (Zalviso®)  has been discontinued as the company has made a decision not to commercialise sufentanil in Ireland. 27/06/2018